IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

NCT05073250 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Inert Non Hodgkin's Lymphoma

Interventions

DRUG: IBI376
BIOLOGICAL: Rituximab

Sponsor

Chinese PLA General Hospital